Recce Pharmaceuticals Ltd. has reached a milestone in its endeavor to combat antimicrobial resistance with the successful batch completion of RECCE® 327 (R327) under good manufacturing practices (GMP). 

The company's lead candidate, R327, marks a new era in synthetic anti-infectives, with the patented manufacturing process now yielding 5,000 GMP doses per week.

Arthur Kollaras, Head of Manufacturing at Recce Pharmaceuticals, expressed excitement over the achievement, stating, "We are thrilled to announce the successful batch completion of human pharmaceutical grade R327, representing a crucial step forward in our mission to address the global threat of antimicrobial resistance."

To meet the increased demand for R327 required for clinical studies, Recce Pharmaceuticals temporarily relocated its manufacturing equipment from its Macquarie Park Facility to a third-party cleanroom-GMP facility. This strategic move enabled the production of an elevated quantity of 5,000 R327 doses under GMP, including fill and finish, the final step of the manufacturing cycle.

Typically completed in-house, the manufacturing process for R327 involves transferring the product to a specialist clean room facility for GMP fill and finish. This achievement of producing 5,000 doses per week is pivotal, providing surplus sample material for current Phase 1 and Phase 2 trials, as well as an anticipated future registrational Phase 3 study for diabetic foot ulcer infections.

This accomplishment highlights Recce’s full-spectrum manufacturing capability, demonstrating the versatile and reproducible nature of its patented manufacturing process.

GMP certification ensures compliance with rigorous guidelines set by regulatory authorities such as the US Food and Drug Administration (FDA), guaranteeing that these doses meet the standards necessary for use in Recce's clinical trials. This progress highlights the commitment to advancing this innovative antibiotic for patients in need and represents a significant step toward the Company’s Investigational New Drug (IND) submission.

GMP covers all aspects of production, ensuring the quality and consistency of every unit of medicine. Without GMP, it would be impossible to ensure that each unit of medicine is of the same high quality as those tested in the laboratory.